Old Web
English
Sign In
Acemap
>
authorDetail
>
Mary Pinder-Schenck
Mary Pinder-Schenck
GlaxoSmithKline
Lung cancer
Internal medicine
Common Terminology Criteria for Adverse Events
Medicine
Randomized controlled trial
3
Papers
60
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma
2018
Cancer Immunology, Immunotherapy
Jhanelle E. Gray
Alberto Chiappori
Charlie C. Williams
Tawee Tanvetyanon
Eric B. Haura
Ben C. Creelan
Jongphil Kim
Theresa A. Boyle
Mary Pinder-Schenck
Farah Khalil
Soner Altiok
Rebecca Devane
David Noyes
Melanie Mediavilla-Varela
Renee Smilee
Emily L. Hopewell
Linda Kelley
Scott Antonia
Show All
Source
Cite
Save
Citations (11)
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer
2016
Investigational New Drugs
Giorgio V. Scagliotti
Jin-Hyoung Kang
David W. Smith
Richard K. Rosenberg
Keunchil Park
Sang-We Kim
Wu Chou Su
Thomas E. Boyd
Donald A. Richards
Silvia Novello
Scott M. Hynes
Scott P. Myrand
Ji Lin
Emily Nash Smyth
Sameera R. Wijayawardana
Aimee Bence Lin
Mary Pinder-Schenck
Show All
Source
Cite
Save
Citations (39)
Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose-Escalation Trial
2015
International Journal of Radiation Oncology Biology Physics
Clara Y.H. Choi
Heather A. Wakelee
Joel W. Neal
Mary Pinder-Schenck
Hsiang-Hsuan Michael Yu
Steven D. Chang
John R. Adler
L.A. Modlin
Griffith R. Harsh
Scott G. Soltys
Show All
Source
Cite
Save
Citations (10)
1